Key Highlights

  • Australian Clinical Labs Limited (ASX:ACL) reported underlying EBIT growth of 1.7% in FY26, with a 20-basis-point improvement in the underlying EBIT margin.
  • Underlying NPAT increased 4.3%, while underlying EPS rose 8.5% to 18.3 cents per share, supported partly by the company's share buyback program.
  • Revenue declined 0.7% amid slower market growth, Medicare funding changes affecting B12 and urine tests, and ongoing optimisation of Australian Clinical Labs' ACC network.
  • FY27 guidance calls for Revenue of $745 million to $765 million and underlying EBIT of $67 million to $73 million, implying a Margin of 9.0% to 9.5%.

Australian Clinical Labs Limited (ASX:ACL) reported a mixed FY26 financial performance, with revenue declining 0.7% while underlying Earnings increased. The company's underlying EBIT rose 1.7%, accompanied by a 20-basis-point expansion in the underlying EBIT margin.

The result reflects the impact of lower market growth and changes to Medicare funding for B12 and urine testing. ACL also continued to optimise its Australian collection centre network. These factors contributed to the reduction in revenue, while operating and labour efficiencies, procurement savings and revenue initiatives helped offset cost pressures.

Underlying NPAT increased 4.3%, supported by improved operating earnings, disciplined cost management and lower depreciation. Underlying Earnings Per Share increased 8.5% to 18.3 cents, with the share buyback contributing to the increase in per-share earnings.

Market Conditions Affect Revenue

ACL reported that its Medicare Benefits Schedule outlays declined 1.0% during FY26, compared with market growth of 0.3%. The company noted that the second half presented a different trend, with ACL's MBS outlays 0.3% above market growth during H2FY26.

The broader pathology market continues to be influenced by Medicare-funded activity, general practitioner attendance levels and changes in government funding. ACL expects market growth in FY27 to remain modest, reflecting the recent pace of Medicare service activity and GP attendances.

Against this backdrop, the company plans to pursue growth in profitable Market Share through net additions to its Australian collection centre network.

Operational Initiatives Support Margins

ACL's FY26 performance included several measures aimed at improving operating efficiency. Procurement savings and workforce management contributed to the company's ability to manage cost pressures, while revenue initiatives supported earnings despite lower reported sales.

For FY27, the company plans to continue implementing measures aimed at addressing labour costs associated with gender undervaluation and the 4.75% wage increase linked to Modern Awards.

Upfront episode billing is expected to increase revenue while reducing bad debts. ACL also plans to increase prices on tests not funded through the MBS. Additional initiatives include its Lab of the Future program, artificial intelligence applications, workforce alignment with activity levels and further improvements in labour ratios.

Capital Returns and Dividend

Capital management remained an important component of ACL's FY26 strategy. During the year, the company returned $47.1 million to shareholders through dividends and the repurchase of 9.3 million shares.

The Board declared a final fully franked Dividend of 9.25 cents per share, an increase of 0.25 cents compared with FY25. When combined with the interim dividend, the final FY26 dividend represents 69% of underlying NPAT.

The final dividend has a Record Date of 3 September 2026 and is scheduled for payment on 23 September 2026. ACL also intends to continue its on-market buyback program during FY27, subject to periodic assessment of funding requirements, strategic investments and stay-in-business Capital expenditure.

FY27 Guidance and Cost Environment

ACL expects FY27 revenue to be between $745 million and $765 million, while underlying EBIT is forecast at $67 million to $73 million. The guidance corresponds to an underlying EBIT margin of 9.0% to 9.5%.

The outlook assumes similar first-half and second-half seasonality to FY26 and modest market growth. The company also expects its strategic initiatives to contribute to revenue generation and efficiency improvements.

The guidance does not include the final stage of the gender undervaluation adjustment for pathology collectors, scheduled for 1 January 2027. ACL intends to assess the effect and work on further operating and revenue measures to offset the associated cost impact.

Conclusion

Australian Clinical Labs' FY26 results show the company's ability to improve underlying earnings despite lower revenue and a challenging pathology market environment. Margin expansion was supported by operational efficiencies, procurement savings, labour management and revenue initiatives, while the buyback contributed to higher earnings per share. For FY27, ACL is targeting further operational improvements alongside modest market growth and selective expansion of profitable market share. The company's ability to manage labour-cost increases, execute revenue initiatives and maintain capital discipline will remain central to its financial performance during the coming year.